December 2019—Hematogenix announced the availability of the assessment of B-cell maturation antigen by flow cytometry and immunohistochemistry at its facilities in China, Asia, Europe, and the United States.
“We have successfully validated multiple BCMA assays by both flow cytometry and immunohistochemistry in selected indications, including multiple myeloma. With the use of these two platforms to assess BCMA, we can consistently provide a broad menu of testing services to support cancer research,” Hytham Al-Masri, MD, CEO and founder of Hematogenix, said in a company statement.
The BCMA IHC assay has been validated on FFPE tissue blocks, including decalcified bone marrow core biopsies as a single stain and as a dual stain with other biomarkers such as CD138. Multiple BCMA flow cytometry assays have been validated on bone marrow aspirate, alone or as part of a broader multiple myeloma minimal residual disease panel.
Hematogenix, 708-444-0444